Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

KIRYAT ONO, ISRAEL and EDISON, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced it has entered into a definitive merger agreement (the "Merger Agreement") with Pharma Two B Ltd., a late-clinical stage private Israeli company that is developing P2B001, an innovative com ...